Unusual Options Activity Signals Bullish Sentiment for Pfizer Shares
23.01.2026 - 07:22:05
A surge in derivatives trading, rather than a major product announcement, has placed Pfizer in the spotlight. This activity coincides with the pharmaceutical giant’s stock reaching a five-week high of approximately $26.10. The shares also traded ex-dividend on January 23, 2026, adding another layer to the current market dynamics.
Beyond the options market, Pfizer has been actively restructuring its portfolio. The company generated $1.9 billion from the sale of its stake in ViiV Healthcare, a specialist in HIV treatments. Concurrently, it entered into a licensing agreement with Novavax, securing rights to the Matrix-M adjuvant technology. The deal involves a $30 million upfront payment, with potential milestone payments reaching up to $500 million.
